Siegfried Holding (SFZN) Stock Overview
Engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
SFZN Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Siegfried Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 94.50 |
| 52 Week High | CHF 118.80 |
| 52 Week Low | CHF 53.70 |
| Beta | 0.71 |
| 1 Month Change | -1.15% |
| 3 Month Change | 4.19% |
| 1 Year Change | 0.53% |
| 3 Year Change | 50.96% |
| 5 Year Change | 121.31% |
| Change since IPO | 1,143.42% |
Recent News & Updates
A Look At The Fair Value Of Siegfried Holding AG (VTX:SFZN)
Jun 14
Does Siegfried Holding (VTX:SFZN) Have A Healthy Balance Sheet?
Apr 29Should You Be Adding Siegfried Holding (VTX:SFZN) To Your Watchlist Today?
Apr 11Recent updates
A Look At The Fair Value Of Siegfried Holding AG (VTX:SFZN)
Jun 14Does Siegfried Holding (VTX:SFZN) Have A Healthy Balance Sheet?
Apr 29Should You Be Adding Siegfried Holding (VTX:SFZN) To Your Watchlist Today?
Apr 11A Look At The Fair Value Of Siegfried Holding AG (VTX:SFZN)
Mar 11Siegfried Holding AG (VTX:SFZN) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Feb 21Earnings Tell The Story For Siegfried Holding AG (VTX:SFZN)
Feb 19
EVOLVE Plus Strategy Under New CEO Marcel Will Focus On M&A And High-Potential Investments
Strategic acquisitions and manufacturing enhancements are set to drive revenue growth and profitability through market expansion and improved services.Siegfried Holding AG's (VTX:SFZN) Price In Tune With Earnings
Nov 09Is Siegfried Holding (VTX:SFZN) Using Too Much Debt?
Sep 12A Look At The Intrinsic Value Of Siegfried Holding AG (VTX:SFZN)
Aug 04Shareholder Returns
| SFZN | CH Life Sciences | CH Market | |
|---|---|---|---|
| 7D | 0.3% | -0.8% | -1.8% |
| 1Y | 0.5% | 3.7% | 0.04% |
Return vs Industry: SFZN underperformed the Swiss Life Sciences industry which returned 3.7% over the past year.
Return vs Market: SFZN matched the Swiss Market which returned 0% over the past year.
Price Volatility
| SFZN volatility | |
|---|---|
| SFZN Average Weekly Movement | 4.4% |
| Life Sciences Industry Average Movement | 5.3% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in CH Market | 8.4% |
| 10% least volatile stocks in CH Market | 2.4% |
Stable Share Price: SFZN has not had significant price volatility in the past 3 months compared to the Swiss market.
Volatility Over Time: SFZN's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1873 | 3,886 | Marcel Imwinkelried | www.siegfried.ch |
Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. The company offers drug substances, including exclusive synthesis that manufactures custom APIs. It also offers an API portfolio, including non-exclusive APIs and pharma-grade substances that focus on anesthetics, pain and addiction treatment applications, and central nervous and respiratory diseases, as well as caffeine for human health and nutrition.
Siegfried Holding AG Fundamentals Summary
| SFZN fundamental statistics | |
|---|---|
| Market cap | CHF 4.14b |
| Earnings (TTM) | CHF 160.06m |
| Revenue (TTM) | CHF 1.29b |
Is SFZN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SFZN income statement (TTM) | |
|---|---|
| Revenue | CHF 1.29b |
| Cost of Revenue | CHF 965.52m |
| Gross Profit | CHF 329.06m |
| Other Expenses | CHF 168.99m |
| Earnings | CHF 160.06m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Aug 21, 2025
| Earnings per share (EPS) | 3.66 |
| Gross Margin | 25.42% |
| Net Profit Margin | 12.36% |
| Debt/Equity Ratio | 50.0% |
How did SFZN perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/22 19:12 |
| End of Day Share Price | 2025/06/20 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Siegfried Holding AG is covered by 23 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Meyer | Baader Helvea Equity Research |
| Volker Bosse | Baader Helvea Equity Research |
| Laura Lopez Pineda | Baader Helvea Equity Research |